SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
TCR2 Therapeutics Inc. (TCRR) .
Criteria proven by this page:
- VALUE (100/100, Pass) — analyst target implies upside (+237.8%).
- Analyst consensus target $5.00 (+237.8% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 42/100 with 1/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — TCRR
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.00
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-3.93
Book Value / Share$0.00
Revenue / Share$0.00
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
Analyst Target$5.00 (+237.8%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$-1.93 |
$0.00 |
$-9.92M |
- |
| 2017 |
$-2.55 |
$0.00 |
$-13.07M |
- |
| 2018 |
$-1.05 |
$0.00 |
$-24.25M |
- |
| 2019 |
$-2.26 |
$0.00 |
$-47.6M |
- |
| 2020 |
$-2.40 |
$0.00 |
$-67.12M |
- |
| 2021 |
$-2.63 |
$0.00 |
$-99.81M |
- |
| 2022 |
$-3.93 |
$0.00 |
$-151.82M |
- |
